Medical Information

Binimetinib, as a MEK inhibitor, commonly has multiple systemic side effects that require different mitigation measures based on their severity. The following provides a detailed explanation of serious side effects that require immediate medical attention, mild reactions that can be self relieved, and targeted prevention strategies to help patients safely take medication.

1. Serious side effects requiring immediate medical attention

The following symptoms require urgent medical intervention: cardiomyopathy related chest pain/lower limb edema, venous thromboembolism (limb swelling and pain), serous retinopathy (blurred vision), interstitial lung disease (dyspnea), liver dysfunction (jaundice), severe bleeding (coughing blood/black stool), and rhabdomyolysis (muscle pain with darkened urine color).

(1) Cardiovascular system

Left ventricular dysfunction is characterized by sudden weight gain and jugular vein engorgement, requiring interruption of treatment and reduction of dosage. Venous thrombosis requires anticoagulant treatment and may be discontinued if necessary.

(2) Eye toxicity

Retinopathy requires monthly ophthalmic examination. If visual distortion occurs, medication should be immediately suspended and the dosage adjusted according to the severity.

2. Mild reactions that can be self relieved

Gastrointestinal symptoms (diarrhea/nausea/vomiting) are usually tolerable, and it is recommended to eat in portions and replenish electrolytes. If it persists for more than 48 hours or is accompanied by dehydration, seek medical attention.

3. Systematic preventive measures

(1) Tumor monitoring

Regular skin check ups should be conducted 6 months before and after treatment, and timely biopsy should be performed if new moles or ulcers are found. Avoid direct sunlight and use SPF50+sunscreen.

(2) Infection prevention

During the period of neutropenia, avoid crowds gathering and report immediately upon contact with the source of infection. Use a soft bristled toothbrush to reduce the risk of gum bleeding.

(3) Fertility management

Women of childbearing age should confirm their pregnancy status before medication, and double contraception is required from the treatment period until 30 days after the last dose. Breastfeeding patients should pause feeding.

(4) Laboratory monitoring

Check liver function, CK enzyme and blood routine every month. Patients with liver function impairment need to reduce their dosage, and for moderate to severe patients, the dosage should be reduced to 30mg twice a day.

4. Precautions for special populations

Elderly patients do not need to adjust the dosage, but need to strengthen cardiac function monitoring. The initial dose for patients with moderate to severe liver damage is halved, and there is no need to adjust it for those with renal dysfunction.